Review




Structured Review

Eigenvector Research Inc pls toolbox version 8.2
Pls Toolbox Version 8.2, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pls+toolbox+8%2E2/pls+toolbox+8+2+1/10__1016_slash_j__lwt__2024__116505-91-12-16
Average 90 stars, based on 1 article reviews
pls toolbox version 8.2 - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

other:

Article Title: Assessment of Tomato Maturity in Different Layers by Spatially Resolved Spectroscopy
Article Snippet: SVMDA models were developed using MATLAB R2017a (The MathWorks, Inc., Natick, MA, USA) combined with PLS Toolbox 8.2 (Eigenvector Research, Inc., Wenatchee, WA, USA).

Article Title: The capability of rare earth elements geochemistry to interpret complex archaeological stratigraphy
Article Snippet: Statistical analyses were carried out using the PLS Toolbox 8.2 for Eigenvector Research Inc., (Wenatchee, WA, USA) running in Matlab R2016b from Mathworks Inc. (Natick, MA, USA).

Article Title: Identification of Apple Varieties Using a Multichannel Hyperspectral Imaging System
Article Snippet: Partial least squares discriminant analysis (PLSDA) models were developed using MATLAB R2017a (The MathWorks, Inc., Natick, MA, USA) coupled with PLS Toolbox 8.2 (Eigenvector Research, Inc., Wenatchee, WA, USA).

Article Title: A practical convolutional neural network model for discriminating Raman spectra of human and animal blood
Article Snippet: Journal of Chemometrics.. 2019;e3184. https://doi.org/10.1002/cem.3184 Abstract A practical convolutional neural network (CNN) model is proposed to discriminate the Raman spectra of human and animal blood.. The proposed network, which discards the pooling layers to avoid loss of data, consists of preprocessing and fully connected classifier layers.

Article Title: Social and technological changes in the ceramic production of the Northern Levant during the LBA/IA transition: New evidence about the Sea People issue through archaeometry
Article Snippet: The transition from the Late Bronze Age (LBA) to the Iron Age (IA) in the Levant is marked by the collapse of the Egyptian and Hittite empires, which dominated the political scene of the 14th–13th century BCE.. The role of the Sea People, groups of migrants who were defeated by the Egyptian king Ramses III around 1175 BCE, is the focal point concerning this period.. After the collapse of the LBA empires, written sources disappeared, and the archaeologists’ primary tool to define cultural processes is to analyze the evolution of pottery.

Article Title: Assessment of tomato soluble solids content and pH by spatially-resolved and conventional Vis/NIR spectroscopy
Article Snippet: Accepted Manuscript Assessment of Tomato Soluble Solids Content and pH by Spatially-Resolved and Conventional Vis/NIR Spectroscopy Yuping Huang, Renfu Lu, Kunjie Chen PII: S0260-8774(18)30205-X DOI: 10.1016/j.jfoodeng.2018.05.008 Reference: JFOE 9252 To appear in: Journal of Food Engineering Received Date: 01 February 2018 Revised Date: 07 May 2018 Accepted Date: 09 May 2018 Please cite this article as: Yuping Huang, Renfu Lu, Kunjie Chen, Assessment of Tomato Soluble Solids Content and pH by Spatially-Resolved and Conventional Vis/NIR Spectroscopy, Journal of (2018), doi: 10.1016/j.jfoodeng.2018.05.008Food Engineering This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form.

Article Title: Soil Specific Surface Area Determination by Visible Near-Infrared Spectroscopy
Article Snippet: All multivariate data analysis was done in Matlab software using PLS toolbox 8.2 (Eigenvector Research Inc., Manson, WA).

Article Title: Chemical and mineralogical analyses on stones from Sagunto Castle (Spain)
Article Snippet: The PLS Toolbox 8.2 for Eigenvector Research Inc. (Wenatchee, WA, USA) running in the software MatlabR2016b from Mathworks Inc. (Natick, MA, USA) was used for statistical treatments.



Similar Products

90
Eigenvector Research Inc pls toolbox version 8.2
Pls Toolbox Version 8.2, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pls+toolbox+8%2E2/pls+toolbox+8+2+1/10__1016_slash_j__lwt__2024__116505-91-12-16
Average 90 stars, based on 1 article reviews
pls toolbox version 8.2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Eigenvector Research Inc software packages pls toolbox 8.2
Software Packages Pls Toolbox 8.2, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pls+toolbox+8%2E2/pls+toolbox+8+7+software/pm37451586-101-21-16
Average 90 stars, based on 1 article reviews
software packages pls toolbox 8.2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Eigenvector Research Inc pls-toolbox 8.2
Pls Toolbox 8.2, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pls+toolbox+8%2E2/pls+toolbox/pm37031872-77-15-17
Average 90 stars, based on 1 article reviews
pls-toolbox 8.2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
MathWorks Inc eigenvectors pls toolbox 8.2
a Heatmaps with unsupervised clustering of SARS-CoV-2-specific antibodies in COVID-19 respiratory (endotracheal tube aspirate (ETA), sputum, or pleural fluid) and plasma samples. b median fluorescence intensity of IgM, IgG, IgA1, and IgA2 antibodies against receptor binding domain (RBD), spike proteins (S), and nucleoprotein (NP) of SARS-CoV-2 (SARS2), SARS-CoV-1 (SARS1), and other human coronaviruses (229E, NL63, OC43, HKU1) between COVID-19 and non-COVID-19 respiratory samples. The bounds of the box plot indicate the 25 th and 75 th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Mann-Whitney test. The P values for IgM against SARS2 RBD, SARS2 S1, SARS2 S2 and SARS2 Trimer S are 0.0103, 0.0143, 0.0143, 0.0103, respectively. The P values for IgG against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 Trimer S and SARS1 NP are 0.0150, 0.0258, 0.0033, 0.0194, 0.0050, 0.0194, 0.0050, respectively. The P values for IgA1 against SARS2 RBD, SARS2 S1, SARS2 S2, and SARS2 Trimer S are 0.0437, 0.0258, 0.0072, 0.0258, respectively. The P values for IgA2 against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 NP are 0.0258, 0.0258, 0.0103, 0.0339, 0.0143, 0.0258, respectively. c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loading plots of ETA and plasma from five COVID-19 and five non-COVID-19 patients with the smallest difference in days post disease onset between ETA and plasma samples. n COVID-19 ETA = 10, n COVID-19 Sputum = 3, n COVID-19 pleural fluid = 1, n Respiratory matched COVID-19 plasma = 13, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Source data are provided as a Source Data file.
Eigenvectors Pls Toolbox 8.2, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pls+toolbox+8%2E2/pmc09120039-300-8-13
Average 90 stars, based on 1 article reviews
eigenvectors pls toolbox 8.2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Eigenvector Research Inc pls toolbox 8.2 software
a Heatmaps with unsupervised clustering of SARS-CoV-2-specific antibodies in COVID-19 respiratory (endotracheal tube aspirate (ETA), sputum, or pleural fluid) and plasma samples. b median fluorescence intensity of IgM, IgG, IgA1, and IgA2 antibodies against receptor binding domain (RBD), spike proteins (S), and nucleoprotein (NP) of SARS-CoV-2 (SARS2), SARS-CoV-1 (SARS1), and other human coronaviruses (229E, NL63, OC43, HKU1) between COVID-19 and non-COVID-19 respiratory samples. The bounds of the box plot indicate the 25 th and 75 th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Mann-Whitney test. The P values for IgM against SARS2 RBD, SARS2 S1, SARS2 S2 and SARS2 Trimer S are 0.0103, 0.0143, 0.0143, 0.0103, respectively. The P values for IgG against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 Trimer S and SARS1 NP are 0.0150, 0.0258, 0.0033, 0.0194, 0.0050, 0.0194, 0.0050, respectively. The P values for IgA1 against SARS2 RBD, SARS2 S1, SARS2 S2, and SARS2 Trimer S are 0.0437, 0.0258, 0.0072, 0.0258, respectively. The P values for IgA2 against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 NP are 0.0258, 0.0258, 0.0103, 0.0339, 0.0143, 0.0258, respectively. c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loading plots of ETA and plasma from five COVID-19 and five non-COVID-19 patients with the smallest difference in days post disease onset between ETA and plasma samples. n COVID-19 ETA = 10, n COVID-19 Sputum = 3, n COVID-19 pleural fluid = 1, n Respiratory matched COVID-19 plasma = 13, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Source data are provided as a Source Data file.
Pls Toolbox 8.2 Software, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pls+toolbox+8%2E2/pls+toolbox+8+7+software/10__1016_slash_j__microc__2021__106150-93-30-34
Average 90 stars, based on 1 article reviews
pls toolbox 8.2 software - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Eigenvector Research Inc pls toolbox 8.2
a Heatmaps with unsupervised clustering of SARS-CoV-2-specific antibodies in COVID-19 respiratory (endotracheal tube aspirate (ETA), sputum, or pleural fluid) and plasma samples. b median fluorescence intensity of IgM, IgG, IgA1, and IgA2 antibodies against receptor binding domain (RBD), spike proteins (S), and nucleoprotein (NP) of SARS-CoV-2 (SARS2), SARS-CoV-1 (SARS1), and other human coronaviruses (229E, NL63, OC43, HKU1) between COVID-19 and non-COVID-19 respiratory samples. The bounds of the box plot indicate the 25 th and 75 th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Mann-Whitney test. The P values for IgM against SARS2 RBD, SARS2 S1, SARS2 S2 and SARS2 Trimer S are 0.0103, 0.0143, 0.0143, 0.0103, respectively. The P values for IgG against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 Trimer S and SARS1 NP are 0.0150, 0.0258, 0.0033, 0.0194, 0.0050, 0.0194, 0.0050, respectively. The P values for IgA1 against SARS2 RBD, SARS2 S1, SARS2 S2, and SARS2 Trimer S are 0.0437, 0.0258, 0.0072, 0.0258, respectively. The P values for IgA2 against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 NP are 0.0258, 0.0258, 0.0103, 0.0339, 0.0143, 0.0258, respectively. c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loading plots of ETA and plasma from five COVID-19 and five non-COVID-19 patients with the smallest difference in days post disease onset between ETA and plasma samples. n COVID-19 ETA = 10, n COVID-19 Sputum = 3, n COVID-19 pleural fluid = 1, n Respiratory matched COVID-19 plasma = 13, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Source data are provided as a Source Data file.
Pls Toolbox 8.2, supplied by Eigenvector Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pls+toolbox+8%2E2/pls+toolbox/pmc07766491-117-15-18
Average 90 stars, based on 1 article reviews
pls toolbox 8.2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


a Heatmaps with unsupervised clustering of SARS-CoV-2-specific antibodies in COVID-19 respiratory (endotracheal tube aspirate (ETA), sputum, or pleural fluid) and plasma samples. b median fluorescence intensity of IgM, IgG, IgA1, and IgA2 antibodies against receptor binding domain (RBD), spike proteins (S), and nucleoprotein (NP) of SARS-CoV-2 (SARS2), SARS-CoV-1 (SARS1), and other human coronaviruses (229E, NL63, OC43, HKU1) between COVID-19 and non-COVID-19 respiratory samples. The bounds of the box plot indicate the 25 th and 75 th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Mann-Whitney test. The P values for IgM against SARS2 RBD, SARS2 S1, SARS2 S2 and SARS2 Trimer S are 0.0103, 0.0143, 0.0143, 0.0103, respectively. The P values for IgG against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 Trimer S and SARS1 NP are 0.0150, 0.0258, 0.0033, 0.0194, 0.0050, 0.0194, 0.0050, respectively. The P values for IgA1 against SARS2 RBD, SARS2 S1, SARS2 S2, and SARS2 Trimer S are 0.0437, 0.0258, 0.0072, 0.0258, respectively. The P values for IgA2 against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 NP are 0.0258, 0.0258, 0.0103, 0.0339, 0.0143, 0.0258, respectively. c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loading plots of ETA and plasma from five COVID-19 and five non-COVID-19 patients with the smallest difference in days post disease onset between ETA and plasma samples. n COVID-19 ETA = 10, n COVID-19 Sputum = 3, n COVID-19 pleural fluid = 1, n Respiratory matched COVID-19 plasma = 13, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

doi: 10.1038/s41467-022-30088-y

Figure Lengend Snippet: a Heatmaps with unsupervised clustering of SARS-CoV-2-specific antibodies in COVID-19 respiratory (endotracheal tube aspirate (ETA), sputum, or pleural fluid) and plasma samples. b median fluorescence intensity of IgM, IgG, IgA1, and IgA2 antibodies against receptor binding domain (RBD), spike proteins (S), and nucleoprotein (NP) of SARS-CoV-2 (SARS2), SARS-CoV-1 (SARS1), and other human coronaviruses (229E, NL63, OC43, HKU1) between COVID-19 and non-COVID-19 respiratory samples. The bounds of the box plot indicate the 25 th and 75 th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Mann-Whitney test. The P values for IgM against SARS2 RBD, SARS2 S1, SARS2 S2 and SARS2 Trimer S are 0.0103, 0.0143, 0.0143, 0.0103, respectively. The P values for IgG against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 Trimer S and SARS1 NP are 0.0150, 0.0258, 0.0033, 0.0194, 0.0050, 0.0194, 0.0050, respectively. The P values for IgA1 against SARS2 RBD, SARS2 S1, SARS2 S2, and SARS2 Trimer S are 0.0437, 0.0258, 0.0072, 0.0258, respectively. The P values for IgA2 against SARS2 RBD, SARS2 S1, SARS2 S2, SARS2 Trimer S, SARS2 NP, SARS1 NP are 0.0258, 0.0258, 0.0103, 0.0339, 0.0143, 0.0258, respectively. c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loading plots of ETA and plasma from five COVID-19 and five non-COVID-19 patients with the smallest difference in days post disease onset between ETA and plasma samples. n COVID-19 ETA = 10, n COVID-19 Sputum = 3, n COVID-19 pleural fluid = 1, n Respiratory matched COVID-19 plasma = 13, n Non-COVID-19 ETA = 5, n Non-COVID-19 sputum = 1. Source data are provided as a Source Data file.

Article Snippet: Partial least squares discriminant analysis (PLSDA), performed in Eigenvectors PLS toolbox 8.2 in Matlab 2017b, was used in conjunction with Elastic-Net, described above, to identify and visualize signatures that distinguish categorical outcomes (COVID-19 diagnosis, NIH scores, drug therapies).

Techniques: Clinical Proteomics, Fluorescence, Binding Assay, MANN-WHITNEY

a Levels of cytokines, soluble IL-6 receptor α (sIL-6Rα), and IL-6:sIL-6Rα ratio, b anti-RBD IgM, IgG, and IgA titres, microneutralization titres and c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loadings plot of antibodies against human coronavirus between mild/moderate and severe/critical COVID-19 patients. d Volcano plot showing fold difference of 83 immunological features in blood samples between mild/moderate and severe/critical COVID-19 patients, and comparisons of cellular subset frequencies and correlation with days stayed in hospital. n Mild-Moderate V1 = 25, n Mild-Moderate V7 = 14, n Severe-Critical V1 = 31, n Severe-Critical V7 = 16. The bounds of the box plot indicate the 25th and 75th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Partial Least-Squares Discriminant Analysis was performed for antibodies measured with multiplex bead array assay. Volcano plots were created using a two-sided Wilcoxon rank-sum test and statistics were corrected with FDR adjustment. Correlation was determined with Spearman’s correlation. V1, hospital admission; V7, hospital discharge. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

doi: 10.1038/s41467-022-30088-y

Figure Lengend Snippet: a Levels of cytokines, soluble IL-6 receptor α (sIL-6Rα), and IL-6:sIL-6Rα ratio, b anti-RBD IgM, IgG, and IgA titres, microneutralization titres and c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loadings plot of antibodies against human coronavirus between mild/moderate and severe/critical COVID-19 patients. d Volcano plot showing fold difference of 83 immunological features in blood samples between mild/moderate and severe/critical COVID-19 patients, and comparisons of cellular subset frequencies and correlation with days stayed in hospital. n Mild-Moderate V1 = 25, n Mild-Moderate V7 = 14, n Severe-Critical V1 = 31, n Severe-Critical V7 = 16. The bounds of the box plot indicate the 25th and 75th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Partial Least-Squares Discriminant Analysis was performed for antibodies measured with multiplex bead array assay. Volcano plots were created using a two-sided Wilcoxon rank-sum test and statistics were corrected with FDR adjustment. Correlation was determined with Spearman’s correlation. V1, hospital admission; V7, hospital discharge. Source data are provided as a Source Data file.

Article Snippet: Partial least squares discriminant analysis (PLSDA), performed in Eigenvectors PLS toolbox 8.2 in Matlab 2017b, was used in conjunction with Elastic-Net, described above, to identify and visualize signatures that distinguish categorical outcomes (COVID-19 diagnosis, NIH scores, drug therapies).

Techniques: Multiplex Assay

a Levels of cytokines, soluble IL-6 receptor α (sIL-6Rα), and IL-6:sIL-6Rα ratio; b anti-RBD IgM, IgG, and IgA titres, microneutralization titres; c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loadings plot of antibodies against human coronaviruses; d cellular immune subset frequencies between COVID-19 patients with or without dexamethasone treatment (with/without remdesivir). n No drug V1 = 24, n No drug V7 = 13, n Drug V1 = 32, n Drug V7 = 17. The bounds of the box plot indicate the 25th and 75th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Partial Least-Squares Discriminant Analysis was performed for antibodies measured with multiplex bead array assay. Volcano plots were created using a two-sided Wilcoxon rank-sum test and statistics were corrected with FDR adjustment. V1, hospital admission; V7, hospital discharge. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

doi: 10.1038/s41467-022-30088-y

Figure Lengend Snippet: a Levels of cytokines, soluble IL-6 receptor α (sIL-6Rα), and IL-6:sIL-6Rα ratio; b anti-RBD IgM, IgG, and IgA titres, microneutralization titres; c Partial Least-Squares Discriminant Analysis (PLSDA) scores and loadings plot of antibodies against human coronaviruses; d cellular immune subset frequencies between COVID-19 patients with or without dexamethasone treatment (with/without remdesivir). n No drug V1 = 24, n No drug V7 = 13, n Drug V1 = 32, n Drug V7 = 17. The bounds of the box plot indicate the 25th and 75th percentiles, the bar indicates medians, and the whiskers indicate minima and maxima. Statistical significance was determined with a two-sided Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Partial Least-Squares Discriminant Analysis was performed for antibodies measured with multiplex bead array assay. Volcano plots were created using a two-sided Wilcoxon rank-sum test and statistics were corrected with FDR adjustment. V1, hospital admission; V7, hospital discharge. Source data are provided as a Source Data file.

Article Snippet: Partial least squares discriminant analysis (PLSDA), performed in Eigenvectors PLS toolbox 8.2 in Matlab 2017b, was used in conjunction with Elastic-Net, described above, to identify and visualize signatures that distinguish categorical outcomes (COVID-19 diagnosis, NIH scores, drug therapies).

Techniques: Multiplex Assay